Daily Recap: Tuesday, 22 October
Tuesday at UEG Week Barcelona 2019 marked the second day of the Scientific Programme!
The day’s scheduled featured exciting Hotspot Symposiums, late-breaking abstract sessions, case-based discussions and live endoscopies.
Tuesday also saw the continuation of the popular Today’s Science, Tomorrow’s Medicine series, with focuses on the microbiome and personalised medicine, current and future trends in faecal microbial transplantation and the impact of antimicrobial resistance on the gut microbiome.
Follow @my_UEG to join in the conversation on Twitter and look back at the day's action.
UEG Rising Stars 2019
Each year, the UEG Scientific Committee and the National Societies Committee jointly select 6-8 emerging clinical scientists as Rising Stars. These scientists are selected based on a track record of international quality research and developing scientific independence. The initiative provides these young researchers with an excellent platform to further develop their career and to take their research to the next level.
After exciting presentations from some of the UEG Rising Stars in Monday’s programme, Jean Charles Nault took to the stage today to receive his award and present a session on ‘Genetics of hepatocellular carcinoma: From risk factors to personalised treatment’.
UEG would like to congratulate this year’s eight worthy Rising Stars, who were:
Thomas Bird, United Kingdom
Johan Burisch, Denmark
Sarwa Darwish Murad, Netherlands
Ihsan Ekin Demir, Germany
Sheraz Markar, United Kingdom
Jean Charles Nault, France
María Jesús Perugorria, Spain
Thomas Reiberger, Austria
Scientific Programme Highlights: The Global Burden of Digestive Diseases
The results of a major study across 195 countries, presented today within a late-breaker session at UEG Week, indicate that global death rates for pancreatic cancer and incidence rates for colorectal cancer both increased by 10% between 1990 and 2017.
The Global Burden of Disease study is the first to provide comprehensive worldwide estimates of the burden, epidemiological features and risk factors of a number of digestive diseases, including pancreatic cancer, colorectal cancer, gastric cancer and IBD. Key findings also included:
- The number of pancreatic cancer cases increased by 130% over the 27-year study period, from 195,000 in 1990 to 448,000 in 2017
- Gastric cancer dropped from the second leading cause of cancer death worldwide to the third, behind both lung and colorectal cancer
- The number of cases of inflammatory bowel disease (IBD) increased 84%, from 3.7 million in 1990 to 6.8 million in 2017
Commenting on the study, Herbert Tilg, Chair of the UEG Scientific Committee, stated, “This analysis provides the most comprehensive picture of the global burden of digestive disease to date. Examining these cross-populational trends offers vital information on the changing burden of disease and aids the correct allocation of resources to improve patient outcomes.”
The study was also published today in The Lancet Gastroenterology & Hepatology.
Scientific Programme Highlights: The Different Faces of Microbiota Along the Digestive Tract
This morning’s abstract-based session on the different faces of microbiota along the digestive tract, one of the hottest current topics in GI, saw a range of discussions on the impact microbiota has on diseases such as gastric cancer, IBD and melanoma.
Ranko Gacesa began the discussion surrounding his abstract ‘composition and function of gut microbiota affects the response rate and survival of melanoma patients treated with immune checkpoint inhibitors’. He showed that, in patients with late stage melanoma, the composition and function of gut microbiota influences the response rate and patient survival in immune checkpoint inhibitor therapy. The study also found that manipulation of microbiome prior to immune checkpoint inhibitor therapy may further increase response rates.
Kaysuyuki Fukade then presented an interesting talk on his abstract ‘next-generation sequencing of faecal microbiota in ulcerative colitis patients together with consanguineous and non-consanguineous relatives’. Kaysuyuki Fukade explained the aim of the study was to investigate the relationship between faecal bacterial species and the development and severity of IBD, in the hope of finding a potential biomarker for use in a clinical practice setting. Results from the study showed that a significant difference was found in 18 species and 10 genera and a potentially interesting relationship between the quantity and diversity of gut microbiota and the development of IBD was obtained.
With gastric cancer being the third leading cause of cancer-related mortality in the world, Ka Shing Cheung wanted to explore the risk of gastric cancer development in diabetes mellitus patients who had received H. pylori eradication. In his study, he found that type 2 diabetes mellitus is associated with a lower risk of gastric cancer among patients who have received H. Pylori eradication therapy. Ka Shing Cheung stated that statins, aspirin and metformin possibly reduce the potential carcinogenic effect of diabetes mellitus on gastric cancer, and that there is an importance in medication adjustment in determining these associations.
Hotspot: Lower GI on Fire!
In Tuesday morning’s Hotspot session, Lower GI on Fire, abstracts covering new research in mortality in microscopic colitis, postoperative recurrence in Crohn’s disease and endoscopic treatment options were presented.
David Bergemalm opened the session with a discussion on ‘markers of systemic inflammation in preclinical ulcerative colitis’. The study showed that protein markers related to systemic inflammation are elevated years before diagnosis of ulcerative colitis and that pre-diagnostic upregulations of inflammatory proteins could, in part, be explained by both genetic and environmental factors.
Nynne Nyboe Andersen then presented information from her study, ‘overall and cause-specific mortality in microscopic colitis: a Danish nationwide matched cohort study’. The results found that there is an increased risk of death in patients with microscopic colitis and that young age at diagnosis, male sex and lymphocytic colitis were associated with higher mortality rates. Nynne Nyboe Andersen highlighted, however, that additional analyses indicated that it may not be microscopic colitis that is associated with higher mortality, but rather the associated factors as a high burden of co-morbidities, as well as lifestyle factors such as smoking.
Peter Higgins concluded the session by presenting his abstract ‘preclinical and clinical efficacy of Olorinab, a peripherally acting, highly selective full agonist of the cannabinoid receptor 2, for the management of visceral pain in inflammatory bowel disease’. The study found that Olorinab reduced visceral hypersensitivity in an animal model of IBD, suggesting that CB2 causes antinociceptive actions in visceral sensory pathways and that Olorinab may provide a future therapeutic approach for chronic abdominal pain.
Celebrating 50 Years of Colonoscopy
Delegates at UEG Week have been provided with the opportunity to celebrate 50 years of colonoscopy by visiting an interactive exhibition that showcases five decades of advancement in the procedure. Visitors are taken on a fascinating journey into the past, present and future of colonoscopy through fine art, engaging storytelling, interactive memorabilia and state-of-the-art science. At the heart of the exhibition lies the impact that colonoscopy has had on patients’ lives, including testimonials, anecdotes and hopes for the future.
Since the first colonoscopy 50 years ago, the procedure has become a crucial tool in the prevention and detection of gastrointestinal diseases, including colorectal cancer. However, despite significant advances, there is huge variation in uptake across Europe which demonstrates how colonoscopy is still not being fully utilised.
Paul Fockens, UEG President, commented “We have come a long way since the introduction of this important technique. Colonoscopy is a potentially life-saving procedure for many patients and has a vital role to play in enhancing digestive health. Today we celebrate scientific dedication and cutting-edge technology to care for patients.”